All In Biotech

Drug Trial Radar · NCT07355218

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

202

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

May 25, 2029

Study completion May 25, 2029

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.

Conditions

  • Systematic Lupus Erythematosus
  • Cutaneous Lupus Erythematosus

Interventions

  • EnpatoranDrug

    Participants will receive a dose of Enpatoran orally twice daily from Day 1 to Day 168.

  • PlaceboDrug

    Participants will receive a single oral dose of a placebo matching Enpatoran tablet twice daily from Day 1 to Day 168.

  • Standard of care (SoC)Drug

    Participants will receive Investigator-recommended SoC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70 Response, Defined as >= 70 Percent (%) Decrease in CLASI-A Score From BaselineTime frame: At Week 24

Locations

70 sites in 20 countries. Site status is shown where the registry gives one.

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California · Recruiting

  • Omega Research Debary, LLC

    DeBary, Florida · Recruiting

  • Centre for Rheumatology, Immunology and Arthritis

    Fort Lauderdale, Florida · Recruiting

  • South Florida Rheumatology

    Hollywood, Florida · Recruiting

  • GTL Medical And Research Group

    Miami, Florida · Recruiting

  • Bolanos Clinical Research

    Pembroke Pines, Florida · Recruiting

  • Vantage Clinical Trials

    Tampa, Florida · Recruiting

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana · Recruiting

  • Accurate Clinical Research Inc. - Lake Charles

    Lake Charles, Louisiana · Recruiting

  • Oakland Hills Dermatology

    Auburn Hills, Michigan · Recruiting

  • Arthritis and Osteoporosis Consultants of the Carolinas II, LLC

    Charlotte, North Carolina · Recruiting

  • Superior Clinical Research, LLC

    Smithfield, North Carolina · Recruiting

  • North Texas Center for Clinical Research

    Frisco, Texas · Recruiting

  • Prolato Clinical Research Center

    Houston, Texas · Recruiting

  • Accurate Clinical Research

    Humble, Texas · Recruiting

  • Monash Medical Centre Clayton

    Clayton, Victoria, Australia · Recruiting

  • Universitair Ziekenhuis Gent - UZG

    Ghent, Belgium · Recruiting

  • Hospital Alemão Oswaldo Cruz

    São Paulo, Brazil · Recruiting

  • RDSS Ricardo Diaz Scientific Solution

    São Paulo, Brazil · Recruiting

  • L2IP - Instituto de Pesquisas Clínicas Ltda.

    Brasília, Federal District, Brazil · Recruiting

  • A2Z Clinical Centro Avancado de Pesquisa Clinica

    Campinas, São Paulo, Brazil · Recruiting

  • DCC 1 Sevlievo EOOD

    Sevlievo, Bulgaria · Recruiting

  • DCC "Alexandrovska", EOOD

    Sofia, Bulgaria · Recruiting

  • The Medical Arts Health Research Group - 300128547

    Kelowna, British Columbia, Canada · Recruiting

  • Fujian Provincial Hospital

    Fuzhou, Fujian, China · Recruiting

  • Nanfang Hospital of Southern Medical University - 300165627

    Guangzhou, Guangdong, China · Recruiting

  • The Second Hospital of Hebei Medical University - 300184836

    Shijiazhuang, Hebei, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Baotou Medical College

    Baotou, Inner Mongolia, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Qilu Hospital of Shandong University - 300163463

    Jinan, Shandong, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Fakultni nemocnice u sv. Anny v Brne - Dept of I. Dermatovenerologicka klinika

    Brno, Czechia · Recruiting

  • Prof.MUDr.Petr Arenberger,DrSc.MBA

    Prague, Czechia · Recruiting

  • MEDICAL PLUS s.r.o.

    Uherské Hradiště, Czechia · Recruiting

  • Universitaetsklinikum Tuebingen - Hautklinik

    Tübingen, Baden-Wurttemberg, Germany · Recruiting

  • Klinikum Oldenburg AoeR - Universitatsklinik f Dermatologie u. Allergologie

    Oldenburg, Lower Saxony, Germany · Recruiting

  • Helios Klinikum Wuppertal - Klinik fuer Dermatologie, Venerologie

    Wuppertal, North Rhine-Westphalia, Germany · Recruiting

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.